Cargando…

Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment

Colon-targeted oral drug delivery systems (CDDSs) are desirable for the treatment of ulcerative colitis (UC), which is a disease with high relapse and remission rates associated with immune system inflammation and dysregulation localized within the lining of the large bowel. However, the success of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yipeng, Wang, Liying, Wang, Zi-Dan, Zhou, Quan, Zhou, Xuefei, Zhou, Tianhua, Guan, Yi-Xin, Liu, Xiangrui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152766/ https://www.ncbi.nlm.nih.gov/pubmed/37127609 http://dx.doi.org/10.1186/s12951-023-01889-0

Ejemplares similares

Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis
por: Zhou, Hong, et al.
Publicado: (2018)

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
por: Lichtenstein, Gary R.
Publicado: (2015)

Colon Delivery of Budesonide Using Solid Dispersion in Dextran for the Treatment and Secondary Prevention of Ulcerative Colitis in Rat
por: Varshosaz, Jaleh, et al.
Publicado: (2010)

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis
por: Iborra, Marisa, et al.
Publicado: (2014)

Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
por: Maconi, Giovanni, et al.
Publicado: (2021)

Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy
por: Shibuya, Tomoyoshi, et al.
Publicado: (2019)

Lentinan-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis
por: Lin, Meisi, et al.
Publicado: (2021)

Use of Budesonide in the Treatment of Microscopic Colitis
por: Tangri, Vikram, et al.
Publicado: (2010)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Nintedanib-Induced Colitis Treated Effectively With Budesonide
por: Amini, Afshin, et al.
Publicado: (2020)

Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis
por: Naganuma, Makoto, et al.
Publicado: (2016)

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T., et al.
Publicado: (2017)

Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
por: Naganuma, Makoto, et al.
Publicado: (2019)

Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles
por: Naeem, Muhammad, et al.
Publicado: (2015)

Lack of effect of methotrexate in budesonide-refractory collagenous colitis
por: Münch, Andreas, et al.
Publicado: (2013)

Budesonide-Related Iatrogenic Cushing’s Syndrome in Microscopic Colitis
por: Tripathi, Kartikeya, et al.
Publicado: (2017)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Pectin Film Coated Pellets for Colon-targeted Delivery of Budesonide: In-vitro/In-vivo Evaluation in Induced Ulcerative Colitis in Rat
por: Varshosaz, Jaleh, et al.
Publicado: (2012)

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T, et al.
Publicado: (2017)

Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study
por: Miyazaki, Ryosuke, et al.
Publicado: (2022)

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
por: Hughes, Michael S., et al.
Publicado: (2019)

Macrophage-evading and tumor-specific apoptosis inducing nanoparticles for targeted cancer therapy
por: Liu, Zimo, et al.
Publicado: (2023)

Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice
por: Xian, Shiyun, et al.
Publicado: (2023)

Correction: Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study
por: Miyazaki, Ryosuke, et al.
Publicado: (2022)

Expression of Concern: Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
Publicado: (2023)

Cell surface‐anchored syndecan‐1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis
por: Zhang, Yan, et al.
Publicado: (2016)

Ulcerative colitis and thrombocytosis: Case report and literature review
por: Zhou, Yaqi, et al.
Publicado: (2023)

Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed Budesonide
por: Kubo, Kimitoshi, et al.
Publicado: (2020)

Resolution of Anastomotic Ulceration and Profound Bleeding by Endoscopic Cauterization and Oral Budesonide
por: Xi, Dong, et al.
Publicado: (2023)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study
por: Rosiou, Konstantina, et al.
Publicado: (2021)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Anti-inflammatory and anti-oxidant properties of Melianodiol on DSS-induced ulcerative colitis in mice
por: Shen, Jinhuang, et al.
Publicado: (2022)

The oral bacterial microbiota facilitates the stratification for ulcerative colitis patients with oral ulcers
por: Xu, Jun, et al.
Publicado: (2023)

Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models
por: Hasan, Nihal, et al.
Publicado: (2023)

Asymptomatic and Persistent Elevation of Pancreatic Enzymes in an Ulcerative Colitis Patient
por: Liverani, Elisa, et al.
Publicado: (2013)

Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis
por: Zhang, Xiao-Fei, et al.
Publicado: (2021)

Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
por: Hibi, Toshifumi, et al.
Publicado: (2020)

Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study
por: Jesionowski, Maciej, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_udg8gqvcd3hm9jq8jdjj4mt219